An update to Quantib Prostate 2.1, Quantib Prostate 3.0 reportedly facilitates workflow advances and offers a variety of tools, ranging from artificial intelligence (AI)-based segmentation to PI-RADS scoring support, to help improve interpretation of prostate magnetic resonance imaging (MRI).
The Food and Drug Administration (FDA) has granted 510(k) clearance to Quantib Prostate 3.0 (RadNet), an artificial intelligence (AI)-based software that may bolster radiology workflow and interpretation of prostate magnetic resonance imaging (MRI).
Key features for Quantib Prostate 3.0, an update to Quantib Prostate 2.1 software, include an improved algorithm for prostate and subregion segmentation and automated lesion drawing on the PI-RADS sector map, according to RadNet.
The company adds that other benefits for enhancing the quality and speed of prostate MRI reporting include PSA (prostate-specific antigen) density calculation, one-click segmentation of lesion candidates, and precise registration and movement correction.
“The (clearance) of Quantib Prostate 3.0 represents another step forward in advancing prostate cancer care by bringing the latest in AI technology to MRI interpretation,” noted Gregory Sorenson, M.D., the president of RadNet’s AI Division. “With the increasing recognition of the important role MRI plays in prostate cancer diagnosis, we believe physicians will value the power that this software puts in their hands.”
(Editor’s note: For related content, see “Emerging Prostate and Brain MRI AI Platform Gets FDA Nod” and “Can Explainable AI Enhance Diagnosis and PI-RADS Classification of Prostate Cancer on MRI?”)
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
What a New PSMA PET/CT Study Reveals About Local PCa Treatment and High-Risk Recurrence
May 16th 2025For patients at high-risk for biochemical recurrence of prostate cancer, PSMA PET/CT findings revealed that 77 percent had one or more prostate lesions after undergoing local radiation therapy or radical prostatectomy, according to a recent study.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.